Relief Therapeutics Unveils Reorganized Executive Leadership to Bolster Pipeline Development

Relief Therapeutics Holding SA announced a significant reshuffling of its executive team aimed at enhancing its operational capabilities to support its pipeline development projects. The announcement was made on May 8, 2024, in Geneva, where the company is based.

The newly formed executive committee sees Andrew Einhorn stepping in as the part-time Chief Financial Officer (CFO). Einhorn possesses considerable expertise in financial roles across various public and private life science entities. Melinda Keegan assumes the position of Chief Human Resources Officer, upgrading her previous advisory role at Relief to lead human resources fully. Giorgio Reiner, with substantial R&D background, will serve as the new Chief Scientific Officer, having transitioned from the same role at APR following its acquisition by Relief. Paolo Galfetti has been shifted from COO to Chief Business Officer, reflecting the strategic redirection of the company, and Vincenzo Gallo joins as the head of legal and compliance.

The board finalized these changes as part of a broader corporate restructuring tagged as a "RESET" aimed at streamlining Relief’s operations to foster success in developing treatments for rare diseases. The company anticipates that these changes will support its goals well into 2026, based on its current financial strategies and projections.